Molecular tests, epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and programmed death-ligand 1 (PD-L1) expression have also been investigated in patients with early-stage NSCLC [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.